Period of time： 2014年1期
Publisher： Springer Publishing Company
Founded in： 1983
Total resources： 32
ISSN： 0167-6997
Subject： R9 Pharmacy
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Investigational New Drugs,volume 24,issue 1
Menu
By Brandon Esther,Sparidans Rolf,Guijt Kees-Jan,Löwenthal Sjoerd,Meijerman Irma,Beijnen Jos,Schellens Jan in (2006)
Investigational New Drugs,volume 24,issue 1 , Vol. 24, Iss. 1, 2006-01 , pp.
Access to resources
Recommend
By Janković Dragana,Pesić Milica,Marković Jasna,Kanazir Selma,Marković Ivanka,Rakić Ljubisav,Ruždijić Sabera in (2006)
Investigational New Drugs,volume 24,issue 1 , Vol. 24, Iss. 1, 2006-01 , pp.By Laarhoven H.,Gambarota G.,Heerschap A.,Lok J.,Verhagen I.,Corti A.,Toma S.,Stampino C.,Kogel A.,Punt C. in (2006)
Investigational New Drugs,volume 24,issue 1 , Vol. 24, Iss. 1, 2006-01 , pp.Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis
By Garcia Agustin,Iqbal Syma,Quinn David,Edwards Susan,Lenz Heinz,Weber Jeff in (2006)
Investigational New Drugs,volume 24,issue 1 , Vol. 24, Iss. 1, 2006-01 , pp.Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma
By Vuky Jacqueline,Isacson Christina,Fotoohi Mehran,Cruz Jason,Otero Henry,Picozzi Vincent,Malpass Thomas,Aboulafia David,Jacobs Andrew in (2006)
Investigational New Drugs,volume 24,issue 1 , Vol. 24, Iss. 1, 2006-01 , pp.A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma
By Lewis Karl,Thompson John,Weber Jeffrey,Robinson William,O'Day Steven,Lutzky Jose,Legha Sewa,Floret Simon,Ruvuna Francis,Gonzalez Rene in (2006)
Investigational New Drugs,volume 24,issue 1 , Vol. 24, Iss. 1, 2006-01 , pp.